Barclays PLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% during ...

EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...